Patents of the popular pain killer kratom have been obtained by the scientist in Japan. It is a very famous medicinal plant grown in Southeast Asia, and researchers of Josai University and Chiba University say that the properties of this herb are similar to opium and the same cell receptors are involved in both cases. However, it is a better choice when the concern is the side effects of the product. In comparison with opiates, there are no such devastating side effects from the use of the herb.
Derivation Of The Compound:
In the year 2000, Japanese researchers extracted and analyzed the compounds in the herb. One of the compounds identified in the leaves of the kratom, or Mitragyna Speciosa, the tree was 7-hydroxymitragynine. The compound has stronger characteristics than what other painkillers have.
How Was The Compound Of The Herb Distinct?
In the case of poppies, a significant side effect is the paralyzation of the gastrointestinal system, by which the limitation of the drug is seen later, and that is not experienced when kratom is used. After being satisfied with the constituents of the herb, researchers performed some chemical alterations to make it usable in a better way as a pharmaceutical.
Rights to use the plant
Josai University and Chiba National University both have three patents of the drugs that are derived from this herb. The patents that have been issued to them include US patent 8247428 which was published on 21 August 2012, Japanese patent 5308352 which was published on 27 May 2013 and US patent 86480090 which was issued on February 11, 2014.
The claim regarding 7-hydroxymitragynine in the US patents is as matter, and the drugs derived from that can be used as human pharmaceuticals as well as veterinary drugs. According to this claim, all the drugs are its part which consists of kratom compounds from 0.1% to 100%. These include all the pills, creams or sprays, etc.
Drugs Are Being Developed:
Josai and Chiba National Universities are located in the metropolitan area of Tokyo, and the University of Chiba is a semi-government university while the other one is under private ownership. The good news is that the patents are not only approved but also the compounds are being developed as well. A drug that has been created from the kratom plant, named MGM-16, is available and being experimented with on animals.
Hiromitsu Takayama of Chiba Pharmaceutical Sciences School is recorded as the leading inventor of the patents, and no Thai inventor is involved in it. There is silence regarding the benefit sharing from all the documents of the patents.
Appropriate Benefit Sharing:
The intellectual property that is claimed by both the universities is said to be the consequence of the innovation and knowledge that comes from the medicines and the traditional users of Southeast Asia, but the proper benefit sharing cannot be suggested by any information so far which is necessary for the Josai and Chiba Universities to let the public be aware of the details so that the evaluation can be done for their effectiveness.